BSE Live
Mar 20, 16:01Prev. Close
2946.15
Open Price
2946.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 20, 15:56Prev. Close
2943.90
Open Price
2973.20
Bid Price (Qty.)
2904.70 (1058)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Ajanta Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 1,180.06 | 1,096.95 | 699.85 | 900.54 | 902.09 | |
| Net CashFlow From Operating Activities | 1,053.80 | 735.35 | 736.29 | 542.34 | 466.99 | |
| Net Cash Used In Investing Activities | -349.60 | 105.02 | -501.31 | -66.04 | -162.68 | |
| Net Cash Used From Financing Activities | -715.71 | -1,047.70 | -105.12 | -457.30 | -268.90 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -11.51 | -207.33 | 129.86 | 19.00 | 35.41 | |
| Cash And Cash Equivalents Begin of Year | 61.78 | 268.85 | 139.83 | 119.88 | 84.95 | |
| Cash And Cash Equivalents End Of Year | 50.27 | 61.52 | 269.69 | 138.88 | 120.36 |
16.03.2026
13.03.2026
06.02.2026
04.02.2026
03.02.2026
Ajanta Pharma Consolidated December 2025 Net Sales at Rs 1,374.84 crore, up 19.95% Y-o-Y
03.02.2026
Ajanta Pharma Standalone December 2025 Net Sales at Rs 1,206.59 crore, up 9.5% Y-o-Y
10.11.2025
Ajanta Pharma Standalone September 2025 Net Sales at Rs 1,220.24 crore, up 8.09% Y-o-Y
04.11.2025
Ajanta Pharma Consolidated September 2025 Net Sales at Rs 1,353.73 crore, up 14.08% Y-o-Y
12.07.2023
Ajanta Pharma Q1 PAT seen up 9.1% YoY to Rs 190.5 cr: Nirmal Bang
13.07.2022
Ajanta Pharma Q1 PAT may dip 12.7% YoY to Rs 151.6 cr: ICICI Direct
11.01.2019
Ajanta Pharma Q3 PAT may dip 35.1% YoY to Rs. 95.8 cr: ICICI Direct
12.10.2018
Ajanta Pharma Q2 PAT may dip 16.5% YoY to Rs. 110.1 cr: ICICI Direct
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
20.03.2026
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
20.03.2026
20.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth